Charles River Laboratories International Inc. has launched the Charles River Incubator Program (CIP), designed to support early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies.
 
“The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offering knowledge, connectivity, and priority access to the Charles River portfolio,” said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River.
 
Building on the success of the Company’s established global Cell and Gene Therapy (CGT) Accelerator Program (CAP), the CIP focuses on nurturing innovative start-up and early-stage biotechnology companies. The objective of the CIP is to form a strong foundation for commercial viability as its participants gain momentum with the goal of imparting cost-effective, consultative regulatory and quality expertise, personnel training initiatives, and enabling access to laboratory space and equipment.
 
The CIP and CAP are reinforced by the Company’s Global Innovation Center of Excellence (CoE), strategically positioned and fully integrated at the heart of Charles River’s extensive virtual and physical network.